|
TIMM22 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.48509999964297E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.26720000048763E-07 |
| Normal-vs-Stage2 |
1.484800E-01 |
| Normal-vs-Stage3 |
9.09000000048898E-07 |
| Normal-vs-Stage4 |
1.40489999633786E-08 |
| Stage1-vs-Stage2 |
2.536600E-03 |
| Stage1-vs-Stage3 |
9.567000E-01 |
| Stage1-vs-Stage4 |
3.914500E-02 |
| Stage2-vs-Stage3 |
6.016800E-03 |
| Stage2-vs-Stage4 |
2.369900E-04 |
| Stage3-vs-Stage4 |
6.371800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.83820000332346E-08 |
| Normal-vs-AfricanAmerican |
2.017600E-02 |
| Normal-vs-Asian |
4.697700E-03 |
| Caucasian-vs-AfricanAmerican |
1.762830E-01 |
| Caucasian-vs-Asian |
6.301900E-02 |
| AfricanAmerican-vs-Asian |
9.770200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.70713999999572E-05 |
| Normal-vs-Female |
1.34480000024695E-07 |
| Male-vs-Female |
8.482400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.88500000450642E-08 |
| Normal-vs-Age(41-60Yrs) |
7.99099999948538E-07 |
| Normal-vs-Age(61-80Yrs) |
2.199900E-04 |
| Normal-vs-Age(81-100Yrs) |
1.027420E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.246800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.269200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.922400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.281600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.549400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.893600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.091700E-02 |
| Classical-VS-Follicular |
1.252030E-01 |
| Classical-VS-Other |
4.044200E-01 |
| Classical-VS-Normal |
6.50370000077061E-08 |
| Tall-VS-Follicular |
2.843400E-03 |
| Tall-VS-Other |
9.688200E-01 |
| Tall-VS-Normal |
7.36949945512322E-10 |
| Follicular-VS-Other |
2.857400E-01 |
| Follicular-VS-Normal |
5.316700E-03 |
| Other-VS-Normal |
3.783400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.43240000000245E-05 |
| Normal-vs-N1 |
1.21999965685404E-10 |
| N0-vs-N1 |
4.17890000000698E-05 |
|
|
